Trials / Completed
CompletedNCT07025577
A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions
A Phase 1, Open-Label, Fixed-Sequence, Randomized Study to Assess the Tolerability and Safety of Subcutaneously Administered Immunoglobulin G With Varying Injection Conditions
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 82 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the safety and tolerability of SC administration of IgG in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Immunoglobulin G | Participants will receive SC administrations of IgG |
Timeline
- Start date
- 2025-06-02
- Primary completion
- 2025-08-08
- Completion
- 2025-09-03
- First posted
- 2025-06-17
- Last updated
- 2025-09-10
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT07025577. Inclusion in this directory is not an endorsement.